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BACKGROUND: Physiological assessment with pressure wire pullback can characterize coronary artery disease (CAD) with 
a focal or diffuse pattern. However, the clinical relevance of this distinction is unknown. We use data from the ORBITA 
trial (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) to test 
if the pattern of CAD predicts the placebo-controlled efficacy of percutaneous coronary intervention (PCI) on stress 
echocardiography ischemia and symptom end points.
METHODS: One hundred sixty-four patients in ORBITA underwent blinded instantaneous wave-free ratio (iFR) pullback 
assessment before randomization. Focal disease was defined as a ≥0.03 iFR unit drop within 15 mm, rather than over a 
longer distance. Analyses were performed using regression modeling.
RESULTS: In the PCI arm (n=85), 48 were focal and 37 were diffuse. In the placebo arm (n=79), 35 were focal and 44 were diffuse. 
Focal stenoses were associated with significantly lower fractional flow reserve (FFR) and iFR values than diffusely diseased 
vessels (mean FFR and iFR, focal 0.60±0.15 and 0.65±0.24, diffuse 0.78±0.10 and 0.88±0.08, respectively, P<0.0001). With 
adjustment for this difference, PCI for focal stenoses resulted in significantly greater reduction in stress echo ischemia than PCI for 
diffuse disease (P<0.05). The effect of PCI on between-arm pre-randomization adjusted exercise time was 9.32 seconds (95% 
CI, −17.1 to 35.7 seconds; P=0.487). When stratified for pattern of disease, there was no detectable difference between focal and 
diffuse CAD (Pinteraction=0.700). PCI improved Seattle Angina Questionnaire angina frequency score and freedom from angina 
more than placebo (P=0.034; P=0.0035). However, there was no evidence of interaction between the physiological pattern of 
CAD and these effects (Pinteraction=0.436; Pinteraction=0.908).
CONCLUSIONS: PCI achieved significantly greater reduction of stress echocardiography ischemia in focal compared with 
diffuse CAD. However, for symptom end points, no such difference was observed.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02062593.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
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Clinical outcome trials which have supported the use of invasive coronary physiology apply diagnostic cut-points to dichotomize decision-making for revas-
cularization in stable coronary artery disease (CAD).1–3 
Fractional flow reserve (FFR) and the instantaneous 
wave-free ratio (iFR) assess the pressure gradient 
across a vessel, as an objective index of severity of CAD. 
However, atherosclerosis within a vessel is more com-
plex than is described by a singular FFR or iFR value. 
Both focal and diffuse patterns of disease are well rec-
ognized; but their impact on the efficacy of revasculariza-
tion is not well understood.
The pattern of CAD may be assessed anatomi-
cally (using quantitative coronary angiography [QCA] 
or intravascular imaging), or physiologically, using inva-
sive pressure wire pullback. Physiological assessment 
characterizes the pattern of pressure loss longitudinally 
throughout a diseased coronary artery. iFR pullback 
offers lesion-specific assessment by quantifying the 
contribution of epicardial resistance apportioned to each 
vessel segment.4,5 By permitting assessment of the pres-
sure gradient at any given point along the vessel, the 
pattern of disease can then be characterized as focal, 
diffuse, or a mixed pattern.4
It is plausible that percutaneous coronary interven-
tion (PCI) of focal stenoses provides greater physio-
logical and symptomatic benefits than PCI of diffusely 
diseased vessels. This may be for a variety of reasons, 
for example, it may result in shorter stented segments 
which are more easily optimized, or it may reflect a 
lower burden of atherosclerosis and microvascular 
disease. However, the efficacy of PCI for treatment of 
symptoms in focal and diffuse patterns of stable CAD 
has not been studied with placebo control.
The ORBITA trial (Objective Randomised Blinded 
Investigation With Optimal Medical Therapy of Angio-
plasty in Stable Angina) was the first placebo-controlled 
trial of PCI for stable CAD. It showed that PCI was effec-
tive in normalizing the anatomic and hemodynamic fea-
tures of a coronary stenosis; yet when compared with 
placebo, the effects on exercise time and symptoms 
were smaller than expected.6
In a prespecified analysis from ORBITA, the associa-
tion between pre-randomization FFR and iFR and the 
clinical end points was studied.7 As might be expected, 
progressively lower, more ischemic, pre-randomiza-
tion FFR and iFR values were associated with greater 
improvements in stress echocardiography ischemia with 
placebo-controlled PCI. However, surprisingly, there was 
no association between pre-randomization FFR and iFR 
and the placebo-controlled benefit of PCI on exercise 
time, symptoms, or quality of life.
In this analysis, we use iFR pullback data and angi-
ographic criteria to stratify the results of ORBITA to 
determine whether the placebo-controlled efficacy of 




The ORBITA trial was approved by the London-Central 
Research Ethics Committee; the design of the trial has been 
previously described.6 All subjects gave informed consent. The 
data, analytical methods, and study materials will not be made 
available to other researchers.
Invasive Physiological Assessment
Patients underwent auditory isolation with over-the-ear head-
phones playing music. Invasive physiological assessments were 
Nonstandard Abbreviations and Acronyms
CAD coronary artery disease
DEFINE-PCI  Physiological Assessment of Coro-
nary Stenosis Following PCI
FFR fractional flow reserve
iFR instantaneous wave-free ratio
ORBITA  Objective Randomised Blinded Inves-
tigation With Optimal Medical Therapy 
of Angioplasty in Stable Angina
PCI percutaneous coronary intervention
QCA quantitative coronary angiography
SAQ Seattle Angina Questionnaire
WHAT IS KNOWN
• Pressure wire pullback characterizes the physiolog-
ical pattern of epicardial coronary artery disease as 
focal or diffuse.
• In the ORBITA trial (Objective Randomised Blinded 
Investigation With Optimal Medical Therapy of 
Angioplasty in Stable Angina), percutaneous cor-
onary intervention was highly effective in relieving 
myocardial ischemia; yet in comparison to placebo, 
its benefits for symptomatic end points were smaller 
than expected.
WHAT THE STUDY ADDS
• Focal stenoses are associated with significantly lower 
fractional flow reserve and instantaneous wave-free 
ratio values than diffusely diseased vessels.
• When this difference is adjusted for, percutaneous 
coronary intervention offers significantly greater reduc-
tion of stress echocardiography ischemia in focal 
rather than in diffuse pressure wire pullback patterns.
• However, despite this difference, stratifying patients 
according to the pattern of coronary artery disease 
(focal versus diffuse) does not seem to be an effective 
means of predicting placebo-controlled symptomatic 
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completed with the primary operator, a consultant interventional 
cardiologist, blinded to their results as previously discussed.7 In 
brief, this was to ensure that patients with a clinically represen-
tative range of values for FFR and iFR were randomized so that 
the placebo-controlled efficacy of PCI could be investigated 
across a full range of FFR and iFR values to investigate the 
cut-points for improvement in angina.
Following iFR and FFR assessment and return of Pd/Pa 
ratio to baseline, a blinded manual iFR pullback manoeuvre was 
recorded under resting conditions. The target pullback speed 
was 1 mm/second to bring the pressure sensor back to the 
tip of the guiding catheter. A drift check was then recorded. 
Where the Pd/Pa ratio fell outside of the range 1.00±0.02, the 
wire was re-normalized and blinded iFR, FFR, and iFR pullback 
assessments repeated with a further drift check performed.
Randomization Procedure
After completion of physiological assessment, pharmacotherapy 
was administered to a deep level of conscious sedation. Once 
confirmed, patients were randomized 1:1 to PCI or a placebo 
procedure with blinding techniques as previously described.6 In 
the PCI arm, iFR and FFR were remeasured after revascular-
ization, with the operator blinded to the results. Patients and all 
subsequent medical caregivers remained blinded to treatment 
allocation until the end of the follow-up period.
Study End Points and Follow-Up
Follow-up was performed at the end of a 6-week blinded period 
as previously described.6
Blinded Analysis of iFR Pullback Data
To characterize the physiological pattern of disease, each iFR 
pullback trace was assessed twice by 6 interventional cardi-
ologists (R.A.L., N.R., T.W., Y.A., C.M.C., H.S.) who were blinded 
to subject identifiers, treatment allocation, the coronary angio-
gram, each other’s opinion and their own first opinion.
Each assessor was asked to grade the pattern of disease as 
focal, diffuse, or mixed pattern of disease. We applied a previ-
ously published definition from the DEFINE-PCI (Physiological 
Assessment of Coronary Stenosis Following PCI) Study.8 In 
brief, focal disease was defined as ≥0.03 iFR unit drop within 
15 mm, rather than over a longer distance.
QCA Analysis of Lesion Length
To provide a separate, angiographic assessment of the pat-
tern of CAD, 3 independent investigators (Y.A., C.K., and A.A.) 
performed QCA analysis of the target vessel in each subject. 
The lesion length was calculated in each case. Where tandem 
stenoses were present within the same vessel, the sum of 
the lesion lengths was taken. The investigators were blinded 
to each other’s opinion, the iFR pullback tracing and the ran-
domization arm.
Dobutamine Stress Echocardiography
Dobutamine stress echocardiography was performed twice in 
each patient, once before randomization and again at the end 
of the 6-week blinded follow-up period. The patient, sonog-
rapher, and physician performing the study were blinded to 
treatment allocation, as were 6 cardiac imaging consultants 
who reported each study.9
Statistical Analysis
This stratified analysis of ORBITA consists of all patients 
randomized in the ORBITA trial with pre-randomization iFR 
pullback.
All analysis has been performed with isolated “focal” disease 
tested against a combined group of patients with “diffuse” or 
“mixed” disease indicated by iFR pullback. We chose this model 
of analysis to optimally test the hypothesis that PCI would offer its 
greatest benefit in those patients with an isolated focal stenoses 
by physiological criteria and no diffuse disease. To be classified as 
a “focal” disease pattern for analysis, the majority opinion (at least 
4) from the first assessment by the 6 raters needed to be “focal”. 
All traces not meeting these criteria were considered to incorpo-
rate diffuse disease: these traces formed the “diffuse” category.
For the anatomic classification, lesion length, as calculated 
by QCA, was treated as a continuous variable and tested for its 
impact on the placebo controlled benefit of PCI on stress echo 
score and symptom end points.
The Seattle Angina Questionnaire (SAQ) scale for angina 
frequency was derived from individual patient responses in 
accordance with published guidelines.10 Freedom from angina 
was defined from the SAQ as previously described.11
Regression models were used to provide increased statisti-
cal power and test the interaction between pattern of CAD as 
assessed by iFR pullback and QCA calculated lesion length on 
the placebo-controlled benefit of PCI on the stated end points.12 
A model was fitted for each end point. For exercise time, a least 
squares model was fitted, whereas a proportional odds ordinal 
logistic model was used for SAQ angina frequency, freedom 
from angina, and stress echo score. The latter model accommo-
dates for possible floor and ceiling effects of angina frequency 
as an end point. The pre-randomization values were modeled 
with a restricted cubic spline with 3 knots (placed at 25%, 50%, 
and 75% of the data) with the presence of focal or diffuse dis-
ease allowed to interact with the randomization arm.12,13
All analyses which compared focal and diffuse categories 
were adjusted for the baseline physiology by including a term 
for the iFR or FFR (as specified in the results) in the model. This 
allowed us to test the association of the pattern, as opposed to 
the severity of CAD, on the stated end points.
The inter- and intraobserver agreement between 6 asses-
sors’ grading of iFR pullback traces was calculated using Fleiss’ 
Kappa.
The Open Source statistical programming environment R 
was used for all statistical analyses.14 The package rms15 was 
used for regression modeling and ggplot2 for all graphs.16
RESULTS
The ORBITA trial randomized 200 patients to PCI 
(n=105) or a placebo procedure (n=95). iFR pullback 
traces were not available for all patients because iFR 
pullback technology was not available at every recruiting 
site from the start of the recruitment period. In addition, 
in 3 patients, the lesion could not be crossed with a pres-
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intimal disruption requiring immediate PCI. An iFR pull-
back trace was therefore available for 164 patients, of 
which 85 were randomly allocated to the PCI arm and 79 
to the placebo procedure.
Patient Demographics
Patient demographics are shown in Table 1.
Procedural Characteristics
Procedural characteristics are shown in Table 2.
Pattern of Disease as Assessed by iFR Pullback
One hundred sixty-four iFR pullback traces were assessed 
by 6 raters, resulting in 984 individual trace assessments 
from which a consensus was calculated. In the PCI arm 
(n=85), 48 (56%) were classified as focal and 37 (44%) 
were classified as diffuse. In the placebo arm (n=79), 35 
(44%) were focal and 44 (56%) were diffuse.
Study End Points
Relationship of Physiological Pattern of Disease 
and Change in Dobutamine Stress Echo Score With 
Placebo-Controlled PCI
Paired iFR pullback and dobutamine stress echocardiog-
raphy data were available in 131 patients. When assessed 
with invasive physiology, focal stenoses were associated 
with significantly lower pre-randomization FFR and iFR 
values than diffusely diseased vessels (focal stenoses 
mean FFR and iFR 0.60±0.15 and 0.65±0.24, diffuse 
lesions mean FFR and iFR 0.78±0.10 and 0.88±0.08, 
respectively, P<0.0001; Table 2).
Across the cohort, PCI resulted in significantly larger 
improvement in stress echocardiography documented 
ischemia in comparison to a placebo procedure, OR, 3.44 
(95% CI, 1.83–6.47, P<0.0001). After adjustment for 
the difference in pre-randomization FFR and iFR values 
between focal and diffuse stenoses, PCI for focal steno-
ses offered significantly greater reduction in stress echo 
ischemia than PCI for diffuse disease. This effect was 
consistent when adjusted for baseline iFR (P=0.020) or 
baseline FFR (P=0.032) values (Figure 1).
Exercise Time
Paired exercise time data and iFR pullback assess-
ments were available for 158 patients (84 in the PCI 
arm and 74 in the placebo arm). In this cohort, the 
estimated effect of PCI over placebo on exercise time 
using regression modeling was 9.32 seconds (95% 
CI, -17.1 to 35.7 seconds; P=0.487). For this relatively 
small effect, there was no detectable evidence of inter-
action between a focal disease pattern and the effect 
of PCI on exercise time increment after adjustment for 
baseline iFR (Pinteraction=0.700, Figure 2A) or base-
line FFR (Pinteraction=0.615, Figure IA in the Data 
Supplement).
Table 1. Patient Demographics at Enrollment
Focal Diffuse
PCI (n=48) Placebo (n=35) All (n=83) PCI (n=37) Placebo (n=44) All (n=81)
Age 64.6±8.9 65.3±8.9 64.9±8.8 65.9±10.0 65.8±7.1 65.8±8.5
Male 36 (75) 25 (71.4) 61 (73.5) 23 (62.2) 32 (72.7) 55 (67.9)
Hypertension 33 (68.8) 25 (71.4) 58 (69.9) 27 (73.0) 31 (70.5) 58 (71.6)
Hypercholesterolemia 32 (66.7) 21 (60.0) 53 (63.9) 32 (86.5) 31 (70.5) 63 (77.8)
Diabetes 6 (12.5) 8 (22.8) 14 (16.9) 6 (16.2) 10 (22.7) 16 (19.8)
Previous MI 4 (8.3) 4 (11.4) 8 (9.6) 0 (0.0) 3 (6.8) 3 (3.7)
Previous PCI 4 (8.3) 4 (11.4) 8 (9.6) 5 (13.5) 9 (20.5) 14 (17.3)
Canadian Cardiovascular Society Angina Grade
 I 0 (0.0) 2 (5.7) 2 (2.4) 1 (2.7) 0 (0.0) 1 (1.2)
 II 27 (56.2) 20 (57.1) 47 (56.6) 24 (64.9) 26 (59.1) 50 (61.7)
 III 21 (43.8) 13 (37.1) 34 (41.0) 12 (32.4) 18 (40.9) 30 (37.0)
 Angina duration, mo 8.4±9.4 8.0±8.1 8.3±8.9 12.6±23.9 8.9±7.7 10.6±17.1
Clinical pre-enrollment positive 
functional test (any)
26 (54.2) 15 (42.9) 41 (49.4) 21 (56.8) 19 (43.2) 40 (49.4)
 ETT 14 (29.2) 5 (14.3) 19 (22.9) 6 (16.2) 8 (18.2) 14 (17.3)
 MIBI 6 (12.5) 5 (14.3) 11 (13.3) 3 (8.1) 5 (11.4) 8 (9.9)
 DSE 6 (12.5) 5 (14.3) 11 (13.3) 12 (32.4) 5 (11.4) 17 (21.0)
 MRI perfusion study 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.7) 1 (1.2)
Values indicate n (%) or mean±SD. DSE indicates dobutamine stress echocardiography; ETT, exercise tolerance test, MI, myocardial infarction; MIBI, nuclear medicine 
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Seattle Angina Questionnaire Angina Frequency 
Score
Paired SAQ angina frequency data and iFR pullback 
were also available for 158 patients (84 in the PCI arm 
and 74 in the placebo arm). In this cohort, PCI signifi-
cantly improved SAQ angina frequency score over a pla-
cebo procedure (odds ratio, 1.88 [95% CI, 1.05–3.37]; 
P=0.034). However, there was no statistically significant 
evidence of interaction between a focal disease pattern 
and the effect of PCI on angina frequency when adjusted 
for baseline iFR (Pinteraction=0.436, Figure 2B), or 
baseline FFR (Pinteraction=0.586, Figure IB in the Data 
Supplement).
Freedom From Angina
Within this cohort, PCI was more likely to result in patient-
reported freedom from angina than placebo (odds ratio, 
2.90 [95% CI, 1.42–5.92]; P=0.0035). However, there was 
no detectable evidence of interaction between the presence 
of a focal disease pattern and the effect of PCI on the likeli-
hood of achieving freedom from angina after adjustment 
for baseline iFR (P  interaction=0.908, Figure 2C) or FFR 
(P interaction=0.797, Figure IC in the Data Supplement).
Impact of Lesion Length as Assessed by QCA on 
Placebo-Controlled Efficacy of PCI
Blinded QCA lesion length assessments were performed 
in 163 of the 164 patients (99.3%) included in this 




(n=35) All (n=83) PCI (n=37)
Placebo 
(n=44) All (n=81)
Left anterior descending 31 (64.6) 19 (54.3) 50 (60.2) 27 (73.0) 39 (88.6) 66 (81.5)
Right coronary 7 (14.6) 10 (28.6) 17 (20.5) 6 (16.2) 2 (4.5) 8 (9.9)
Circumflex 5 (10.4) 4 (11.4) 9 (10.8) 3 (8.1) 2 (4.5) 5 (6.2)
First OM 3 (6.3) 0 (0.0) 3 (3.6) 0 (0.0) 0 (0.0) 0 (0.0)
First diagonal 1 (2.1) 1 (2.9) 2 (2.4) 1 (2.7) 1 (2.3) 2 (2.5)
Intermediate 1 (2.1) 1 (2.9) 2 (2.4) 0 (0.0) 0 (0.0) 0 (0.0)
Serial lesions on angiography 7 (14.6) 5 (14.3) 12 (14.5) 6 (16.2) 6 (13.6) 12 (14.8)
Quantitative coronary angiography
 Lesion length (mm) 14.7 ± 7.0 12.7 ± 5.3 13.9 ± 6.4 15.6 ± 8.2 14.9 ± 6.9 15.2 ± 7.5
  No. patients with diameter stenosis ≥ 50% 
by QCA
46 (95.8) 32 (91.4) 78 (94.0) 26 (70.3) 35 (79.5) 61 (75.3)
 Diameter stenosis by QCA 69.9 ± 12.0 69.8 ± 14.6 69.8 ± 13.1 55.2 ± 9.9 57.6 ± 9.7 56.5 ± 9.8










































 No. Patients with iFR ≤ 0.89 40 (83.3) 32 (91.4) 72 (86.7) 16 (43.2) 27 (61.4) 43 (53.1)
Characteristics of PCI





































 No. patients with post-iFR >0.89 47 (97.9) - - 34 (91.9) - -
Values indicate n (%) or mean±SD. FFR indicates fractional flow reserve; iFR, instantaneous wave-free ratio; IQR, interquartile range; OM, obtuse marginal; PCI, 
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analysis. This provided an angiographic, as opposed to 
a physiological stratification of the pattern of disease. 
There was no significant impact of lesion length on the 
placebo-controlled impact of PCI on stress echo score 
(Pinteraction=0.799, Figure 3A). Furthermore, when 
lesion length was used as a predictor of the placebo-
controlled impact of PCI on symptom end points, there 
was no significant effect on exercise time (Pinterac-
tion=0.947, Figure 3B), SAQ angina frequency score 
(Pinteraction=0.891, Figure 3C) or freedom from angina 
(Pinteraction=0.879, Figure 3D).
Inter and Intraobserver Agreement in Assessment of 
Pattern of Disease by iFR Pullback and Dobutamine 
Stress Echocardiography Reporting
There was good interobserver agreement across 6 raters, 
each assessing 164 individual pullback traces (Fleiss’ 
Kappa 0.603). The intraobserver agreement between 
an individual assessor’s first and second assessments of 
pullback traces was also good (Fleiss’ Kappa 0.799).
The mean inter- and intraobserver absolute differ-
ences of the stress echocardiography score were 1.3 
and 0.9 stress echocardiography units, respectively.
Sensitivity Analysis
Our sensitivity analysis restricted the eligible cohort to 
those with pre-randomization physiological values of 
FFR ≤0.80 (Table I in the Data Supplement), and iFR 
≤0.89 (Table II in the Data Supplement).
DISCUSSION
This is the first placebo-controlled data to assess the effi-
cacy of PCI stratified by the physiological pattern of CAD. 
Focal stenoses were associated with significantly lower 
pre-randomization FFR and iFR values than diffusely 
diseased vessels. After adjustment for the difference in 
absolute ischemia, we found that PCI for physiologically 
focal stenoses offered significantly greater improve-
ments in stress echocardiography documented ischemia 
than PCI for physiologically diffuse disease.
However, no such relationship was observed for the 
symptom end points. Specifically, when adjusted for 
baseline iFR and FFR values, there was no detectable 
difference in the placebo-controlled increase in exercise 
time following PCI for physiologically focal compared 









































































































































































































Pinteracon = 0.032Pinteracon = 0.020
Figure 1. Impact of placebo-controlled 
percutaneous coronary intervention 
(PCI) on dobutamine stress 
echocardiography (DSE) ischemia.
A, Impact of PCI and placebo on DSE 
ischemia according to physiological 
pattern of disease, adjusted for baseline 
instantaneous wave-free ratio (iFR) (A(i)) 
and baseline fractional flow reserve (FFR) 
(A(ii)). B, Placebo-controlled impact of 
PCI on DSE ischemia in diffuse and focal 
stenoses, adjusted for baseline iFR (B(i)) 
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with diffuse disease. Similarly, the physiological pattern 
of disease did not predict the placebo-controlled efficacy 
of PCI on angina frequency or freedom from angina.
Our second analysis, which stratified patients 
according to anatomic rather than physiological crite-
ria, showed no association between QCA lesion length 
and the placebo-controlled impact of PCI on stress 
echocardiography ischemia or any symptom end point. 
Physiologically diffuse lesions were only marginally lon-
ger anatomically than physiologically focal stenoses. 
This likely reflects the weak correlation between visual 
assessment of the coronary angiogram and the invasive 
physiological pattern of disease when assessors are 
blinded to the physiological results.
Previous stratified analyses of ORBITA have tested 
the association between severity of pre-randomization 
ischemia and symptomatic improvement following PCI.7,9 
Given that there was no detectable interaction between 
invasive physiology (FFR or iFR) and the efficacy of 
PCI on exercise time or symptoms,7 we performed the 
present analysis to test the hypothesis that PCI may be 
more effective in treating focal stenoses than diffusely 
diseased arteries.
The theory for this assumption is clear: optimal PCI in 
diffuse disease is more challenging because the magni-
tude of physiological benefit per unit of stented segment 
is diminished. Furthermore, residual disease, particularly 
in the distal vessel, may contribute to ischemia, but will 
not be amenable to PCI.
ORBITA has helped our understanding of the rela-
tionship between coronary stenosis, ischemia, and 
symptoms. We assume that restriction of epicardial 
blood flow caused by coronary stenoses, focal or dif-
fuse, results in hemodynamic insufficiency and myocar-
dial ischemia during stress. With sufficient ischemia, a 
wall motion abnormality may become evident. However, 
the mass of ischemic myocardium required to cause 
downstream symptomatic manifestations (angina) was 
previously unknown.
The design of ORBITA allowed the sequence of 
steps in this model to be tested. Invasive physiologi-
cal assessments of ischemia (FFR and iFR) predicted 
the improvement in stress echo ischemia from PCI but 
not placebo-controlled symptomatic benefit.7 However, 
the Dobutamine stress echocardiography-stratified 
analysis of ORBITA showed that at stress echo scores 
of ≥1 (ie, ≥1 segment of hypokinesia), PCI resulted 
in a placebo-controlled reduction in patient-reported 
frequency of angina.9 Overall, this suggests that tar-
geting ischemia testing further downstream, where 
abnormalities reflect the total burden of ischemic myo-
cardium, allows identification of patients that may be 
most likely to benefit symptomatically from PCI. While 
high-precision invasive physiological measurements 
made upstream in the cascade are vessel-specific 
and provide an invaluable measurement of ischemia in 
the catheterization laboratory, they may be too sensi-
tive to make predictions of symptomatic benefit from 
PCI. This may explain the absence of an interaction 
between iFR pullback assessments and the efficacy of 
PCI on symptomatic end points.
However, if we accept that ischemia is a continuum and 
move away from dichotomous cut-points, tools such as 
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Figure 2. Effect of physiological pattern of disease on the impact of placebo-controlled percutaneous coronary intervention 
(PCI) on symptom end points.
The association between pattern of coronary artery disease as assessed by instantaneous wave-free ratio (iFR)-pullback and the benefit of PCI 
over placebo for (A) exercise time, (B) Seattle Angina Questionnaire (SAQ) angina frequency, and (C) SAQ derived freedom from angina, after 
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stable CAD. By preventing the loss of information content 
that occurs through dichotomization, these tools present 
a more complete assessment of vessel characteristics. 
They are also useful for optimization of the hemodynamic 
result of PCI. The DEFINE-PCI study performed blinded 
iFR pullback following angiographically successful PCI, to 
determine the cause of any residual ischemia.8 It found 
that 81.6% of patients with an iFR value <0.90 post-
PCI had untreated focal stenoses. Randomized data are 
required to test the utility of pullback technology. To this 
end, we await the results of the international DEFINE-
GPS trial which will address event end points.17 For symp-
tom end points, blinded studies are required.
The recently reported ISCHEMIA trial showed prog-
nostic clinical equipoise for an invasive versus conserva-
tive strategy in stable CAD.18 Symptom and quality of life 
improvement is now the main goal of revascularization 
in this setting. However, the results of this analysis once 
again show that the relationship between ischemia and 
symptoms is much more complex than we had hoped.
Study Limitations
iFR pullback data were available for 164 of the 200 ran-
domized ORBITA participants (82%). This sample size 
may limit the power of this analysis. iFR pullback, rather 
than FFR pullback was used in this analysis because the 
use of a hyperemic index such as FFR for longitudinal 
vessel analysis has been shown to be limited by hemo-
dynamic cross-talk between serial stenoses in the same 
vessel.19 Resting indices such as iFR pullback appear to 
be less vulnerable to this phenomenon.4,20
Patients were selected for inclusion in the ORBITA 
trial on the basis of single vessel coronary disease, symp-
tomatic angina, and the absence of severe left ventricular 
impairment or severe valvular disease. This is a very spe-
cific cohort chosen because it makes it straightforward 
to draw inferences about the relationship between lesion 
characteristics and the placebo-controlled effect of PCI. 
Moreover, it should be remembered that the majority of 
elective PCI is conducted for single vessel disease.21 It is 
unknown from the present data whether diffuse disease 
Figure 3. Impact of quantitative coronary angiography lesion length on placebo-controlled efficacy of percutaneous coronary 
intervention (PCI) on dobutamine stress echocardiography and symptom end points.
The impact of lesion length on (A) stress echo score, (B) exercise time, (C) Seattle Angina Questionnaire (SAQ) angina frequency, and (D) 
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involving multiple vessels instead of only a single vessel 
would respond any differently to PCI.
The prevalence of diabetes was low across the cohort, 
which may be reflective of the fact that only patients with 
single vessel disease were eligible for enrollment. This is 
unlikely to have artificially reduced the symptomatic effect 
of PCI. Patients with multivessel disease will be eligible for 
inclusion in the ORBITA-2 trial which is currently enrolling.
Interestingly, in this substudy of the ORBITA trial, pla-
cebo-controlled PCI resulted in an improvement in SAQ 
angina frequency score. While there was a trend to this 
relationship in previously published reports7,9 this was not 
statistically significant. This reflects chance differences 
in the cohorts eligible for the analyses.
Operators were blinded to iFR pullback traces during 
the randomization procedure and therefore did not use 
this data to guide PCI. Angiography alone may underesti-
mate the extent of diffuse disease resulting in shorter stent 
length. This is reflected in the procedural characteristics 
which show no difference in stent length between the focal 
and diffuse categories. The results of this analysis should 
be interpreted in this context; physiologically diffuse disease 
may have been underappreciated by the blinded operators 
who could only use angiography and intravascular imaging, 
at their discretion, to guide their procedure. Larger trials are 
needed to study whether PCI guided by unblinded pressure 
wire pullback and co-registration technology, in addition to 
intravascular imaging, can improve outcomes.
It could be argued that a favorable disease pattern in 
combination with a sufficiently low absolute iFR or FFR 
value may identify symptomatic responders to PCI. How-
ever, we have not further stratified diffuse and focal cate-
gories according to their absolute distal iFR value because 
further subdivision of groups is likely to be underpowered. 
The larger sample size offered by the ORBITA-2 trial may 
permit further stratification of results according to disease 
pattern, degree of ischemia and per-vessel analysis (left 
anterior descending, circumflex and right coronary artery).
In the absence of an accepted gold-standard criteria 
to define a focal stenosis, we applied the same definitions 
utilized by the physiology Core Laboratory at the Cardio-
vascular Research Foundation for the DEFINE-PCI study.8 
The result of this analysis is therefore subject to the crite-
ria that were applied for the identification of focal disease. 
Furthermore, pressure wire pullback was not automated 
and instead was performed manually. Differences in the 
speed of pullback may have made precise determination 
of a 15 mm distance, as specified in our definition of focal 
disease, more challenging. Contemporary co-registration 
technology was not available for the majority of the time 
period of the trial but may aid similar analyses in the future.
Conclusions
In this analysis of ORBITA, stratified by the physiologi-
cal pattern of disease, focal stenoses were associated 
with significantly lower pre-randomization FFR and iFR 
values than diffusely diseased vessels. With adjust-
ment for this difference, placebo-controlled PCI for 
focal stenoses offered significantly greater reduction in 
stress echocardiography ischemia than PCI of diffusely 
diseased arteries. However, we did not observe any 
independent effect of the pattern of CAD on the pla-
cebo-controlled benefit of PCI on symptom end points. 
The absence of an interaction between physiological 
pattern of disease and symptom improvement from 
placebo-controlled PCI may reflect a weak association 
between invasive hemodynamic changes and symptom 
relief and requires further study.
ARTICLE INFORMATION
Received October 29, 2020; accepted March 25, 2021.
Affiliations
National Heart and Lung Institute, Imperial College London, United Kingdom 
(C.A.R., M.S.-S., H.S., Y.A., T.W., J.P.H., S.G., L.A., C.K., A.N., M.F., R.A., G.C., R.K., R.P., 
N.R., S.N., S.S., D.P.F., R.A.-L.). Imperial College Healthcare NHS Trust, London, 
United Kingdom (C.A.R., M.S.-S., H.S., J.P.H., A.N., M.F., R.A., G.C., R.K., G.K., R.P., 
N.R., I.S.M., S.N., S.S., D.P.F., R.A.-L.). Columbia University Medical Centre, New 
York–Presbyterian Hospital (Y.A.). St. Marianna University School of Medicine, 
Yokohama, Japan (T.W.). Essex Cardiothoracic Centre, Basildon, United Kingdom 
(C.M.C., T.R.K., J.R.D., K.H.T.). University of Sheffield, United Kingdom (A.A.). West 
Hertfordshire Hospitals NHS Trust, Watford, United Kingdom (N.G.K., J.S.). Anglia 
Ruskin School of Medicine, Chelmsford, Essex, United Kingdom (T.R.K., J.R.D.). 
East Sussex Healthcare NHS Trust, Hastings, United Kingdom (R.G.). Royal 
Bournemouth and Christchurch NHS Trust, Bournemouth, United Kingdom (P.O.). 
University Hospital of Wales, Cardiff, United Kingdom (A.S.P.S.). University of Ex-
eter, United Kingdom (A.S.P.S.).
Sources of Funding
The ORBITA trial (Objective Randomised Blinded Investigation With Optimal 
Medical Therapy of Angioplasty in Stable Angina) was funded by grants from 
National Institute for Health Research (NIHR) Imperial Biomedical Research 
Centre, Foundation for Circulatory Health, and Imperial College Healthcare 
Charity. Dr Rajkumar and M. Foley are PhD Training Fellows at the Medical Re-
search Council (MR/S021108/1 and MR/V001620/1), J.P. Howard is a PhD 
Training Fellow at the Wellcome Trust (212183/Z/18/Z), and Dr Nowbar is 
supported by the NIHR Imperial Biomedical Research Centre. Philips Volcano 
supplied the coronary pressure wires. We acknowledge support of the NIHR 
Clinical Research Network and the BHF Centre of Research Excellence at Im-
perial College London.
Disclosures
Outside of the submitted work, Dr Seligman reports research funding from 
Amgen, C.M. Cook reports personal fees from Philips, T.R. Keeble has received 
nonfinancial support from Philips Volcano, A.S.P. Sharp reports personal fees for 
Medtronic and Philips, Dr Petracoreports speakers honoraria from Philips and 
consultancy for Amgen, S. Nijjer reports speaker’s honoraria from Philips, Dr Sen 
reports speaker’s honoraria from Philips, AstraZeneca and Pfizer, Dr Al-Lamee 
reports speaker’s honoraria from Philips and Menarini pharmaceuticals. The other 
authors report no Conflicts.
Supplemental Materials
Online Figure I
Online Tables I and II
REFERENCES
 1. Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, 
Stella PR, Boersma E, Bartunek J, Koolen JJ, et al. Fractional flow reserve 
to determine the appropriateness of angioplasty in moderate coronary 





 http://ahajournals.org by on A
ugust 17, 2021
Rajkumar et al PCI for Focal vs Diffuse Stable CAD
Circ Cardiovasc Interv. 2021;14:e009891. DOI: 10.1161/CIRCINTERVENTIONS.120.009891 August 2021 10
 2. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer M, Klauss V, 
Manoharan G, Engstrøm T, Oldroyd KG, et al; FAME Study Investigators. 
Fractional flow reserve versus angiography for guiding percutaneous 
coronary intervention. N Engl J Med. 2009;360:213–224. doi: 10.1056/ 
NEJMoa0807611
 3. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, 
Möbius-Winkler S, Mobius-Winckler S, Rioufol G, et al; FAME 2 Trial Investi-
gators. Fractional flow reserve-guided PCI versus medical therapy in stable 
coronary disease. N Engl J Med. 2012;367:991–1001. doi: 10.1056/ 
NEJMoa1205361
 4. Nijjer SS, Sen S, Petraco R, Escaned J, Echavarria-Pinto M, Broyd C, 
Al-Lamee R, Foin N, Foale RA, Malik IS, et al. Pre-angioplasty instantaneous 
wave-free ratio pullback provides virtual intervention and predicts hemody-
namic outcome for serial lesions and diffuse coronary artery disease. JACC 
Cardiovasc Interv. 2014;7:1386–1396. doi: 10.1016/j.jcin.2014.06.015
 5. Kikuta Y, Cook CM, Sharp ASP, Salinas P, Kawase Y, Shiono Y, Giavarini A, 
Nakayama M, De Rosa S, Sen S, et al. Pre-angioplasty instantaneous wave-
free ratio pullback predicts hemodynamic outcome in humans with coro-
nary artery disease: primary results of the International Multicenter IFR 
GRADIENT Registry. JACC Cardiovasc Interv. 2018;11:757–767. doi: 
10.1016/j.jcin.2018.03.005
 6. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, 
Keeble T, Mielewczik M, Kaprielian R, Malik IS, et al; ORBITA Investiga-
tors. Percutaneous coronary intervention in stable angina (ORBITA): a dou-
ble-blind, randomised controlled trial. Lancet. 2018;391:31–40. doi: 
10.1016/S0140-6736(17)32714-9
 7. Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, 
Nijjer S, Petraco R, Davies J, Keeble T, et al. Fractional flow reserve and 
instantaneous wave-free ratio as predictors of the placebo-controlled 
response to percutaneous coronary intervention in stable single-vessel 
coronary artery disease. Circulation. 2018;138:1780–1792. doi: 10.1161/ 
CIRCULATIONAHA.118.033801
 8. Jeremias A, Davies JE, Maehara A, Matsumura M, Schneider J, Tang K, 
Talwar S, Marques K, Shammas NW, Gruberg L, et al. Blinded physiological 
assessment of residual ischemia after successful angiographic percutane-
ous coronary intervention: the DEFINE PCI study. JACC Cardiovasc Interv. 
2019;12:1991–2001. doi: 10.1016/j.jcin.2019.05.054
 9. Al-Lamee RK, Shun-Shin MJ, Howard JP, Nowbar AN, Rajkumar C, 
Thompson D, Sen S, Nijjer S, Petraco R, Davies J, et al. Dobutamine stress 
echocardiography ischemia as a predictor of the placebo-controlled effi-
cacy of percutaneous coronary intervention in stable coronary artery dis-
ease: the stress echocardiography-stratified analysis of ORBITA. Circulation. 
2019;140:1971–1980. doi: 10.1161/CIRCULATIONAHA.119.042918
 10. Garratt AM, Hutchinson A, Russell I; Network for Evidence-Based Prac-
tice in Northern and Yorkshire (NEBPINY). The UK version of the Seattle 
Angina Questionnaire (SAQ-UK): reliability, validity and responsiveness. 
J Clin Epidemiol. 2001;54:907–915. doi: 10.1016/s0895-4356(01) 
00352-3
 11. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, 
Zhang W, Hartigan PM, Lewis C, Veledar E, et al; COURAGE Trial Research 
Group. Effect of PCI on quality of life in patients with stable coronary dis-
ease. N Engl J Med. 2008;359:677–687. doi: 10.1056/NEJMoa072771
 12. Harrell F. Regression Modelling Strategies. Springer International Publishing, 
2015.
 13. Liu Q, Shepherd BE, Li C, Harrell FE, Jr. Modeling continuous response 
variables using ordinal regression. Stat Med. 2017;36:4316–4335. doi: 
10.1002/sim.7433
 14. Team RDC. R: A Language and Environment for Statistical Computing. R 
Foundation for Statistical Computing, 2010.
 15. Harrell F. rms: Regression Modeling Strategies. R package version 3.4.3.2018.
 16. Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag, 
2009.
 17. Nguyen J, Matsumura M, Maehara A, Jeremias A. Physiological assess-
ment after PCI: the new routine? Lessons from DEFINE PCI. 2019. 
American College of Cardiology. https://www.acc.org/latest-in-cardiol-
ogy/articles/2019/09/23/08/14/physiological-assessment-after-pci. 
Accessed April 1, 2020.
 18. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, 
Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, et 
al; ISCHEMIA Research Group. Initial invasive or conservative strategy 
for stable coronary disease. N Engl J Med. 2020;382:1395–1407. doi: 
10.1056/NEJMoa1915922
 19. De Bruyne B, Pijls NH, Heyndrickx GR, Hodeige D, Kirkeeide R, Gould KL. 
Pressure-derived fractional flow reserve to assess serial epicardial steno-
ses: theoretical basis and animal validation. Circulation. 2000;101:1840–
1847. doi: 10.1161/01.cir.101.15.1840
 20. Modi BN, Rahman H, Ryan M, Ellis H, Pavlidis A, Redwood S, Clapp B, 
Chowienczyk P, Perera D. Comparison of fractional flow reserve, instanta-
neous wave-free ratio and a novel technique for assessing coronary arteries 
with serial lesions. EuroIntervention. 2020;16:577–583. doi: 10.4244/EIJ- 
D-19-00635
 21. Desai NR, Bradley SM, Parzynski CS, Nallamothu BK, Chan PS, Spertus 
JA, Patel MR, Ader J, Soufer A, Krumholz HM, et al. Appropriate use cri-
teria for coronary revascularization and trends in utilization, patient selec-





 http://ahajournals.org by on A
ugust 17, 2021
